Gene · 2268
Papers1,862
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 1,862
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Computational Prediction of Biomarkers, Pathways, and New Target Drugs in the Pathogenesis of Immune-Based Diseases Regarding Kidney Transplantation Rejection. | Front Immunol | 2021 | 34975915 | PubTator, text mining | PubMed |
| The Regulatory Network of Cyclic GMP-AMP Synthase-Stimulator of Interferon Genes Pathway in Viral Evasion. | Front Microbiol | 2021 | 34966372 | PubTator, text mining | PubMed |
| Use of a Network-Based Method to Identify Latent Genes Associated with Hearing Loss in Children. | Front Cell Dev Biol | 2021 | 34912812 | PubTator, text mining | PubMed |
| Transcriptomics of single dose and repeated carbon black and ozone inhalation co-exposure highlight progressive pulmonary mitochondrial dysfunction. | Part Fibre Toxicol | 2021 | 34911549 | PubTator, text mining | PubMed |
| DNA methylation of ARHGAP30 is negatively associated with ARHGAP30 expression in lung adenocarcinoma, which reduces tumor immunity and is detrimental to patient survival. | Aging (Albany NY) | 2021 | 34910688 | PubTator, text mining | PubMed |
| Cystic Fibrosis: Systems Biology Analysis from Homozygous p.Phe508del Variant Patients' Samples Reveals Perturbations in Tissue-Specific Pathways. | Biomed Res Int | 2021 | 34901273 | PubTator, text mining | PubMed |
| YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. | Int J Mol Sci | 2021 | 34884609 | PubTator, text mining | PubMed |
| Integrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. | Sci Rep | 2021 | 34857786 | PubTator, text mining | PubMed |
| Comprehensive analysis of prognostic immune-related genes and drug sensitivity in cervical cancer. | Cancer Cell Int | 2021 | 34852825 | PubTator, text mining | PubMed |
| Evidence of off-target effects of bosutinib that promote retinoic acid-induced differentiation of non-APL AML cells. | Cell Cycle | 2021 | 34836491 | PubTator, text mining | PubMed |
| Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter? | Cancers (Basel) | 2021 | 34830952 | PubTator, text mining | PubMed |
| Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going? | Front Oncol | 2021 | 34804979 | PubTator, text mining | PubMed |
| Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing. | Exp Mol Med | 2021 | 34782737 | PubTator, text mining | PubMed |
| A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. | Blood Res | 2021 | 34776414 | PubTator, text mining | PubMed |
| Ionizing irradiation-induced Fgr in senescent cells mediates fibrosis. | Cell Death Discov | 2021 | 34772919 | PubTator, text mining | PubMed |
| Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. | Immunotargets Ther | 2021 | 34754837 | PubTator, text mining | PubMed |
| Evaluation of Placentation and the Role of the Aryl Hydrocarbon Receptor Pathway in a Rat Model of Dioxin Exposure. | Environ Health Perspect | 2021 | 34747641 | PubTator, text mining | PubMed |
| Genomic and epigenomic adaptation in SP-R210 (Myo18A) isoform-deficient macrophages. | Immunobiology | 2021 | 34735924 | PubTator, text mining | PubMed |
| Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro. | Front Immunol | 2021 | 34721399 | PubTator, text mining | PubMed |
| Tyrosine phosphorylation of NLRP3 by the Src family kinase Lyn suppresses the activity of the NLRP3 inflammasome. | Sci Signal | 2021 | 34699250 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2268/papers?page=22